Advanced search
Publication Cover
Journal of Market Access & Health Policy Volume 8, 2020 - Issue 1
Journal homepage
855
Views
3
CrossRef citations to date
0
Altmetric
Original Research Article

Use of complete clearance for assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: how baseline lesion count can impact this outcome

Khaled Ezzedinea Department of Dermatology, University Hospital Henri Mondor, Créteil, FranceView further author information
,
Caroline Painchaultb HEOR department, Keyrus Life Science, Levallois-Perret, FranceView further author information
&
Melanie Brignonec Market access and HEOR department, Pierre Fabre, Boulogne-Billancourt, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3351-2312View further author information
ORCID Icon
Article: 1829884 | Received 12 Jun 2020, Accepted 21 Sep 2020, Published online: 09 Oct 2020

References

  • de Berker D, McGregor JM, Mohd Mustapa MF, et al. British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017;176(1):20–6. .
  • Stockfleth E, Kerl H, Zwingers T, et al. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;165(5):1101–1108. .
  • Szeimies RM, Atanasov P, Bissonnette R. Use of lesion response rate in actinic keratosis trials. Dermatol Ther (Heidelb). 2016;6(4):461–464.
  • Traianou A, Ulrich M, Apalla Z, et al. Risk factors for actinic keratosis in eight European centres: a case-control study. Br J Dermatol. 2012;167(Suppl2):36–42. .
  • Dirschka T, Gupta G, Micali G, et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J Dermatolog Treat. 2017;28(5):431–442. .
  • Wolf JE Jr., Rigel DS. Understanding efficacy end-points in studies of field-directed therapy for actinic keratosis. Int J Dermatol. 2013;52(9):1063–1070.
  • Fernandez-Figueras MT, Carrato C, Saenz X, et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol. 2015;29(5):991–997. .
  • Stockfleth E, von Kiedrowski R, Dominicus R, et al. Efficacy and safety of 5-fluorouracil 0.5%/salicylic acid 10% in the field-directed treatment of actinic keratosis: a phase III, randomized, double-blind, vehicle-controlled trial. Dermatol Ther (Heidelb). 2017;7(1):81–96. .
  • Huyke C, Reuter J, Rodig M, et al. Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges. 2009;7(2):128–133.
  • Skov T, Stockfleth E, Szeimies RM, et al. Efficacy endpoints in clinical trials in actinic keratosis. Dermatol Ther (Heidelb). 2018;8(3):425–433. .
  • Stockfleth E, Ulrich C, Lange-Asschenfeldt B, et al. Treatment of multiple, multiform actinic keratoses on the head with imiquimod 5% cream. Eur J Dermatol. 2009;19(4):355–359. .
  • Dohil MA. Efficacy, safety, and tolerability of 4% 5-fluorouracil cream in a novel patented aqueous cream containing peanut oil once daily compared with 5% 5-fluorouracil cream twice daily: meeting the challenge in the treatment of actinic keratosis. J Drugs Dermatol. 2016;15(10):1218–1224.
  • Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157(Suppl 2):34–40. .
  • Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70(2Suppl):22–29.
  • Pierre Fabre data on file. HD-FUDR-045: A Randomized, Evaluator Blinded, Vehicle Controlled, Parallel Group, Dose Ranging Study of the Safety and Efficacy of 4% 5-FU Cream Versus its Vehicle Cream Versus Efudex in the Treatment of Actinic Keratosis. 2005.
  • Pierre Fabre data on file. HD-FUP3S-049: A Randomized, Double-Blind, Vehicle-Controlled Multi-Center Study of the Safety and Efficacy of 4% 5-FU Cream Versus its Vehicle Cream in the Treatment of Actinic Keratosis. 2007.
  • Pierre Fabre data on file. HD-FUP3B-048: A Randomized, Evaluator Blinded, Vehicle-Controlled Multi-Center Study of the Safety and Efficacy of 4% 5-FU Cream Versus its Vehicle Cream Versus Efudex Cream in the Treatment of Actinic Keratosis. 2007.
  • Reynolds KA, Schlessinger DI, Vasic J, et al. Core outcome set for actinic keratosis clinical trials. JAMA Dermatology. 2020 Jan 15;156(3):326. Epub ahead of print.
  • Foley P, Stockfleth E, Peris K, et al. Adherence to topical therapies in actinic keratosis: a literature review. J Dermatolog Treat. 2016;27(6):538–545. .
  • Norrlid H, Norlin JM, Holmstrup H, et al. Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients. J Dermatological Treat. 2018;29(1):68–73. .
  • Heppt MV, Steeb T, Schmitz L, et al. Harmonisation of Outcome Parameters and Evaluation (HOPE) for actinic keratosis: protocol for the development of a core outcome set. Trials. 2019;20(1):589. .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.